[go: up one dir, main page]

CL2017002939A1 - Composiciones farmacéuticas tópicas - Google Patents

Composiciones farmacéuticas tópicas

Info

Publication number
CL2017002939A1
CL2017002939A1 CL2017002939A CL2017002939A CL2017002939A1 CL 2017002939 A1 CL2017002939 A1 CL 2017002939A1 CL 2017002939 A CL2017002939 A CL 2017002939A CL 2017002939 A CL2017002939 A CL 2017002939A CL 2017002939 A1 CL2017002939 A1 CL 2017002939A1
Authority
CL
Chile
Prior art keywords
pharmaceutical compositions
patient
topical pharmaceutical
phase
refers
Prior art date
Application number
CL2017002939A
Other languages
English (en)
Inventor
Leandro L Santos
Mary BEDARD
Michael Quinn DOHERTY
Jon D Lenn
Sujatha D Sonti
Joey Roger THOMAS
Justin E Whiteman
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56081527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002939(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of CL2017002939A1 publication Critical patent/CL2017002939A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS TÓPICAS EN EMULSIÓN, QUE COMPRENDEN UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE 3,5-DIHIDROXI-4- ISOPROPIL-TRANS-ESTILBENO O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, UNA FASE OLEOSA, UNA FASE ACUOSA, UN TENSIOACTIVO, Y UN ANTIOXIDANTE, Y EN DONDE LA COMPOSICIÓN EN EMULSIÓN ES HOMOGÉNEA Y/O EL INGREDIENTE ACTIVO SE SOLUBILIZA EN LA FASE OLEOSA. LA INVENCIÓN SE REFIERE TAMBIÉN A MÉTODOS PARA TRATAR UNA AFECCIÓN O TRASTORNO DERMATOLÓGICO EN UN PACIENTE MEDIANTE LA ADMINISTRACIÓN DE LAS PRESENTES COMPOSICIONES A LA PIEL DEL PACIENTE.</p>
CL2017002939A 2015-05-21 2017-11-20 Composiciones farmacéuticas tópicas CL2017002939A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562165097P 2015-05-21 2015-05-21
US201662324450P 2016-04-19 2016-04-19

Publications (1)

Publication Number Publication Date
CL2017002939A1 true CL2017002939A1 (es) 2018-03-16

Family

ID=56081527

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002939A CL2017002939A1 (es) 2015-05-21 2017-11-20 Composiciones farmacéuticas tópicas

Country Status (35)

Country Link
US (5) US10195160B2 (es)
EP (2) EP3297605B1 (es)
JP (4) JP6863904B2 (es)
KR (2) KR102669247B1 (es)
CN (2) CN114042041B (es)
AU (2) AU2016263161B2 (es)
BR (1) BR112017024934A8 (es)
CA (1) CA2986251A1 (es)
CL (1) CL2017002939A1 (es)
CO (1) CO2017011795A2 (es)
CR (1) CR20170528A (es)
CY (1) CY1125318T1 (es)
DK (1) DK3297605T3 (es)
DO (1) DOP2017000270A (es)
EA (1) EA038624B1 (es)
ES (1) ES2914112T3 (es)
HR (1) HRP20220670T1 (es)
HU (1) HUE059066T2 (es)
IL (3) IL316851A (es)
JO (1) JO3680B1 (es)
LT (1) LT3297605T (es)
MX (2) MX377629B (es)
PE (1) PE20180038A1 (es)
PH (1) PH12017502092A1 (es)
PL (1) PL3297605T3 (es)
PT (1) PT3297605T (es)
RS (1) RS63402B1 (es)
SG (1) SG11201708666RA (es)
SI (1) SI3297605T1 (es)
SM (1) SMT202200224T1 (es)
TW (1) TWI705831B (es)
UA (1) UA125500C2 (es)
UY (1) UY36682A (es)
WO (1) WO2016185428A1 (es)
ZA (1) ZA202007965B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
KR102669247B1 (ko) * 2015-05-21 2024-05-27 더마반트 사이언시즈 게엠베하 국소 제약 조성물
CA3082115A1 (en) * 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof
CN109085257B (zh) * 2018-07-05 2021-04-06 中央民族大学 一种同时定量检测小鼠血浆中黄芪甲苷-iv、环黄芪醇的方法
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
JP6898622B2 (ja) * 2019-01-30 2021-07-07 学校法人神奈川大学 皮膚又は粘膜の外用剤及びその製造方法、並びに皮膚又は粘膜の外用剤の基剤
EP3955889A1 (en) 2019-04-17 2022-02-23 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
KR20220008893A (ko) * 2019-05-15 2022-01-21 레오 파마 에이/에스 피부 홍반성 루푸스의 치료
US20200383887A1 (en) * 2019-06-04 2020-12-10 L'oreal Oxygenate skin treatment system
CA3144947A1 (en) * 2019-06-26 2020-12-30 Locus Oil Ip Company, Llc Multi-functional compositions comprising concentrated acids for enhanced oil and gas recovery
CA3147740A1 (en) * 2019-07-24 2021-01-28 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions
WO2021059281A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
US20220387349A1 (en) * 2019-09-26 2022-12-08 Sol-Gel Technologies Ltd Treatment of cutaneous adverse effects caused by oncological therapy with topical tapinarof compositions
KR20220097429A (ko) * 2019-11-06 2022-07-07 솔-겔 테크놀로지스 리미티드 손발바닥각피증 치료 방법
WO2021100051A1 (en) * 2019-11-24 2021-05-27 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical compositions comprising tapinarof and a pde4 inhibitor
GB202000167D0 (en) * 2020-01-07 2020-02-19 Cytovation As Composition for treatment of neoplastic lesions
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) * 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions
MX2022015792A (es) * 2020-06-24 2023-02-27 Dermavant Sciences GmbH Composiciones farmaceuticas topicas.
CN115867267A (zh) * 2020-06-30 2023-03-28 德米拉公司 RORγt抑制剂和其局部用途
US12440529B2 (en) 2020-09-22 2025-10-14 Alphyn Biologics, Inc. Topical Croton lechleri compositions and their use in the treatment of a bacterial colonization or primary or secondary bacterial infection of an underlying skin disorder
CN116723864A (zh) * 2020-11-23 2023-09-08 德玛万科学有限责任公司 Tapinarof的凝胶、软膏和泡沫配制剂及使用方法
US20240315985A1 (en) * 2021-02-17 2024-09-26 Dermavant Sciences GmbH Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
WO2022183001A1 (en) * 2021-02-25 2022-09-01 Alphyn Biologics Composition for treatment of topical dermatological bacterial skin conditions
CN113797159A (zh) * 2021-10-22 2021-12-17 冠昊生物科技股份有限公司 一种本维莫德乳膏剂及其制备方法和用途
JP2025529076A (ja) * 2022-08-30 2025-09-04 ダーマヴァント サイエンシーズ ゲーエムベーハー ＡｈＲ媒介疾患の治療に使用するタピナロおよびそのアナログ製剤
WO2024124206A1 (en) * 2022-12-08 2024-06-13 Hairdao Payments Llc Topical compositions for treating and preventing hair loss and hair graying
WO2025031935A1 (en) 2023-08-04 2025-02-13 Sandoz Ag Crystalline forms of tapinarof

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5111748A (en) 1974-07-16 1976-01-30 Taisho Pharmaceutical Co Ltd Suchirubenjudotaino seizoho
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
JPS58159410A (ja) 1982-03-18 1983-09-21 Mitsubishi Chem Ind Ltd 抗炎症剤
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5008100A (en) 1989-08-11 1991-04-16 Elizabeth Arden Co., Division Of Conopco, Inc. Oil-in-water emulsions containing polyethylene
US6113921A (en) * 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JPH1072330A (ja) 1996-09-03 1998-03-17 Kansai Kouso Kk チロシナーゼ活性阻害剤及び化粧料
JPH1143436A (ja) * 1997-07-25 1999-02-16 Showa Denko Kk 末梢血流障害予防・治療剤
EP1987809A1 (en) 1998-02-10 2008-11-05 Shiseido Co., Ltd. Oil-in-water type emulsion composition enthaltend Retinoide
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
FR2777183B1 (fr) 1998-04-10 2001-03-02 Oreal Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
AU4084599A (en) 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
DE19842730A1 (de) * 1998-09-18 2000-03-23 Beiersdorf Ag Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl
FR2785284B1 (fr) 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20020054895A1 (en) * 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
DE60043120D1 (de) * 1999-12-06 2009-11-19 Welichem Biotech Inc Polyhydroxystilbene und -stilbenoxide als antipsoriasismittel und proteinkinasehemmer
US7321050B2 (en) 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
FR2811564B1 (fr) * 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
ES2401077T3 (es) 2001-01-18 2013-04-16 Glaxo Group Limited Nuevos derivados 1,2-difenileteno para el tratamiento de enfermedades inmunológicas
CA2452159A1 (en) 2001-07-23 2003-02-06 Galileo Laboratories, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods
RU2212763C2 (ru) * 2001-08-16 2003-09-20 Общество с ограниченной ответственностью "Подсолнечник Технологии" Система открытой оптической связи
WO2003077856A2 (en) * 2002-03-12 2003-09-25 Playtex Products, Inc. Lotion compositions
US20040202634A1 (en) * 2003-03-19 2004-10-14 L'oreal Composition useful for cosmetic or dermatological use containing a block copolymer
ZA200608621B (en) 2004-03-18 2008-06-25 Panacea Biotec Ltd Novel compositions for topical delivery
US20060018861A1 (en) * 2004-07-23 2006-01-26 Minghua Chen Skin care composition
PT1809383E (pt) * 2004-10-19 2008-11-06 Boots Co Plc Composições cosméticas
US20060246098A1 (en) * 2005-03-16 2006-11-02 Srinivasa Rao Stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
KR20070057660A (ko) * 2005-12-01 2007-06-07 롬 앤드 하아스 컴패니 활성물을 안정시키기 위한 수성 폴리머 분산액
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
US20080206155A1 (en) * 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
EP1930499A1 (en) * 2006-12-08 2008-06-11 Cognis IP Management GmbH Tissue paper comprising a softening lotion
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
US9308239B2 (en) 2008-02-26 2016-04-12 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
EP2293787A1 (en) * 2008-04-25 2011-03-16 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
JP2009291133A (ja) * 2008-06-05 2009-12-17 Snow Brand Milk Prod Co Ltd チーズ食品
DK2400951T3 (en) * 2009-02-25 2018-12-03 Mayne Pharma Llc TOPICAL FOAM COMPOSITION
MX359879B (es) * 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
CN101822638A (zh) * 2009-12-01 2010-09-08 河北科技大学 二苯乙烯类化合物的纳米乳及其制备方法
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
EP2542208A1 (en) * 2010-03-01 2013-01-09 Photocure ASA Cosmetic compositions
PH12013500783A1 (en) * 2010-10-21 2022-03-30 Cadila Healthcare Ltd Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
PT2645993T (pt) 2010-12-03 2017-03-03 Allergan Inc Composições de creme farmacêutico compreendendo oximetazolina
WO2013000869A1 (en) 2011-06-27 2013-01-03 Galderma Research & Development New th17 differentiation markers for acne and uses thereof
US20130224268A1 (en) 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
CN102657610A (zh) 2012-05-11 2012-09-12 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯微乳剂及其制备方法
CN102657602B (zh) 2012-05-22 2013-08-07 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN103315958B (zh) 2013-07-19 2014-10-29 河北科技大学 苯烯莫德纳米乳及其制备方法
WO2015085143A2 (en) 2013-12-06 2015-06-11 Stc.Unm Therapeutic agents for skin diseases and conditions
CN103992212B (zh) * 2014-05-29 2015-07-01 河北科技大学 顺式苯烯莫德的合成方法及顺式苯烯莫德的应用
AU2015358910B2 (en) 2014-12-12 2019-01-24 Dermavant Sciences GmbH Novel method of use
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
KR102669247B1 (ko) 2015-05-21 2024-05-27 더마반트 사이언시즈 게엠베하 국소 제약 조성물
CA3082115A1 (en) 2017-11-10 2019-05-16 Dermavant Sciences GmbH Process for preparing tapinarof

Also Published As

Publication number Publication date
JP2024153800A (ja) 2024-10-29
UY36682A (es) 2016-12-30
US11458108B2 (en) 2022-10-04
IL255203A0 (en) 2017-12-31
KR20180008490A (ko) 2018-01-24
CN114042041B (zh) 2023-08-22
TW201705940A (zh) 2017-02-16
US20190192446A1 (en) 2019-06-27
US20200101027A1 (en) 2020-04-02
CN114042041A (zh) 2022-02-15
ES2914112T3 (es) 2022-06-07
MX377629B (es) 2025-03-10
CN107666902B (zh) 2021-09-21
CA2986251A1 (en) 2016-11-24
RS63402B1 (sr) 2022-08-31
CY1125318T1 (el) 2024-12-13
JO3680B1 (ar) 2020-08-27
EP3297605A1 (en) 2018-03-28
HUE059066T2 (hu) 2022-10-28
HRP20220670T1 (hr) 2022-08-19
US20190192445A1 (en) 2019-06-27
TWI705831B (zh) 2020-10-01
UA125500C2 (uk) 2022-04-13
US10426743B2 (en) 2019-10-01
CN107666902A (zh) 2018-02-06
IL316851A (en) 2025-01-01
SI3297605T1 (sl) 2022-08-31
MX2020012595A (es) 2021-02-09
IL282304B2 (en) 2025-04-01
JP2023113829A (ja) 2023-08-16
NZ736602A (en) 2024-10-25
US10195160B2 (en) 2019-02-05
WO2016185428A1 (en) 2016-11-24
EA201792559A1 (ru) 2018-04-30
US20190151255A1 (en) 2019-05-23
SMT202200224T1 (it) 2022-07-21
IL255203B (en) 2021-05-31
KR102669247B1 (ko) 2024-05-27
IL282304B1 (en) 2024-12-01
US11622945B2 (en) 2023-04-11
BR112017024934A2 (pt) 2018-07-31
AU2016263161B2 (en) 2019-02-28
CR20170528A (es) 2018-01-22
DK3297605T3 (da) 2022-06-07
PT3297605T (pt) 2022-05-30
PH12017502092A1 (en) 2018-05-07
EA038624B1 (ru) 2021-09-24
JP6863904B2 (ja) 2021-04-21
IL282304A (en) 2021-05-31
AU2019203627A1 (en) 2019-06-13
KR20240090730A (ko) 2024-06-21
BR112017024934A8 (pt) 2021-03-30
AU2019203627B2 (en) 2020-12-24
MX2017014804A (es) 2018-02-15
EP3297605B1 (en) 2022-05-04
JP2018515561A (ja) 2018-06-14
JP2021105027A (ja) 2021-07-26
LT3297605T (lt) 2022-06-27
DOP2017000270A (es) 2017-12-15
JP7531658B2 (ja) 2024-08-09
ZA202007965B (en) 2022-12-21
HK1245074A1 (en) 2018-08-24
EP4094752A1 (en) 2022-11-30
PL3297605T3 (pl) 2022-07-11
SG11201708666RA (en) 2017-12-28
US11612573B2 (en) 2023-03-28
PE20180038A1 (es) 2018-01-09
AU2016263161A1 (en) 2017-11-16
CO2017011795A2 (es) 2018-02-28
US20160338973A1 (en) 2016-11-24

Similar Documents

Publication Publication Date Title
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
CL2020000747A1 (es) Formulaciones de niraparib.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
MX390954B (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo.
MX2019010757A (es) Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor.
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
BR112015027297A8 (pt) administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
BR112015021334A2 (pt) formulações oculares para entrega de droga ao segmento posterior do olho
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
MX2018001584A (es) Composiciones de solución sólida para aines.
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
CL2019000625A1 (es) Combinación de agonistas de fxr.
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
CL2018001797A1 (es) Formulación galénica que comprende un fármaco tópico
BR112018010489A8 (pt) tratamento para administração via oral, softgel, comprimido ou cápsula, método de redução dos efeitos psicoativos do thc em humanos, e solução ou tintura de lipossomos
MX2017013481A (es) Composicion farmaceutica de liberacion sostenida que contiene rivastigmina.
AR104699A1 (es) Composición farmacéutica tópica en emulsión y su uso para fabricar un medicamento
GT201600072A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
CY1124107T1 (el) Συνδυασμος αδαπαλενης και υπεροξειδιου του βενζολιου για τη θεραπευτικη αντιμετωπιση της σοβαρης ακμης
MX2017014471A (es) Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia.
BR102014028900A8 (pt) produto nanotecnológico de uma formulação lipossomal a base de antioxidantes para o tratamento da lesão pulmonar aguda
UA106472U (uk) Засіб для лікування дерматологічних захворювань